Sponsoring > Sponsoring and sponsorshipEuropean Center for Biotechnology and Bioeconomy (CEBB) Located at the heart of the Bazancourt-Pomacle biorefinery, and supported by the local authorities, the European Center for Biotechnology and Bioeconomy (CEBB) brings together the scientific and technical expertise of four chairs and units from AgroParisTech, CentraleSupélec, NEOMA Business School and URCA for the valorization of by-products from the agri-food industries. To tackle this challenge, the CEBB has many skills in biomass pretreatment (characterization, fractionation, SSF/LSF and extraction/purification), biomass transformation (green chemistry, biotechnology and process engineering), analysis and characterization, and modeling, instrumentation and simulation. Its holistic approach also allows it to study the contribution of the bioeconomy to the ecological transition. Concerning the topics addressed by the CBSO, the following expertise can be specifically mentioned: • Exploration of microbial diversity for known or new microbial strains: microbial physiology, microbial cultures, fermentations, omics and bioinformatics (transcriptomics, genomics, metagenomics, proteomics, metabolomics) • Exploration of enzymatic diversity: molecular biology (cloning, heterologous expression), characterization of enzymes, development of biocatalytic processes (cellulases, hemicellulases, ligninolytic enzymes, (per)oxidases, esterases, pectinases) • Exploration of fungal diversity: physiology, cultures, fermentations (SSF) • Coupling of biocatalytic processes and electrochemistry, coupling of biocatalytic processes and continuous extraction (ISPR) • Fermentation (ethanolic) • Bioproduction of secondary metabolites and molecules of interest (e.g., synthons, pigments) • Enzymatic functionalization-modulation to produce biomolecules and polymers: glycosylation, acylation, dimerization/oligomerization, hydrogenases, oxidation-reduction, transaminases (polyphenols, amines, sugar esters, phenolic esters, alkyl glycosides) • Enzymatic polymerization and degradation of bio-based polymers/materials • Bioreactor and photobioreactor design, bioprocess optimization, population metabolic studies, bioprocess control and instrumentation, digital twin in bioprocesses
 Servier is a global pharmaceutical group governed by a Foundation. Relying on a solid geographical presence and revenue of €4.7 billion in 2020 achieved in 150 countries, Servier employs 22,500 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year.
To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities, from research to support beyond the pill.
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to all patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently under served therapeutic areas, including neurology and oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world's leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified employees. The Company’s 15 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.
The Charles Viollette Industrial Research Chair is carried by UMRt BioEcoAgro. Its objective is to valorize co-products of plant origin by industrial biotechnology tools (fermentation and enzyme biocatalysis) to produce bioactive molecules for applications in the fields of nutrition, health, bioenergy and chemistry.
Genopole is a French biocluster dedicated to research in genetics and biotechnologies in healthcare and the environment. It unites 77 biotech companies, 19 research laboratories and 25 technical platforms, as well as a range of tertiary-level training programs with the University of Évry-Paris Saclay (Data as of end December 2021). Genopole’s objectives are to create and support biotech companies and the transfer of technologies to the industrial sector, favor the development of life sciences research, and promote advanced training programs for those domains. Headed by Gilles Lasserre, Genopole is funded primarily by the French State, the Île-de-France Administrative Region, the Essonne Administrative Department, the Grand Paris Sud Urban Area, the city of Évry-Courcouronnes and the AFM-Téléthon.
|
| Online user: 4 | Privacy |
|
